89 Participants Needed

Pembrolizumab + Epacadostat for Head and Neck Cancer

Recruiting at 72 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Incyte Corporation
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, it mentions the use of protocol-defined prior/concomitant therapy, which might mean some medications could be restricted. It's best to discuss your specific medications with the trial team.

What data supports the effectiveness of the drug combination Pembrolizumab + Epacadostat for head and neck cancer?

Research shows that Pembrolizumab, a drug that helps the immune system fight cancer, is approved for use in head and neck cancer after other treatments have failed. Additionally, combinations of drugs like cisplatin or carboplatin with 5-fluorouracil and cetuximab have been shown to be effective in treating head and neck cancer, suggesting that similar combinations may also be beneficial.12345

Is the combination of pembrolizumab and epacadostat safe for head and neck cancer patients?

The combination of pembrolizumab with other drugs like carboplatin and paclitaxel has been generally well tolerated in patients with head and neck cancer, though some experienced mild to moderate side effects like anemia (low red blood cell count) and hypertension (high blood pressure). Safety data specifically for pembrolizumab and epacadostat together is limited, but pembrolizumab alone has been approved for use in similar conditions, indicating a level of safety in humans.13567

What makes the drug combination of Pembrolizumab and Epacadostat unique for head and neck cancer?

This drug combination is unique because it combines Pembrolizumab, an immune checkpoint inhibitor that blocks PD-1 to help the immune system attack cancer cells, with Epacadostat, an IDO inhibitor that may enhance immune response by reducing immune suppression. This approach is novel compared to traditional chemotherapy, which often has more side effects and less targeted action.138910

What is the purpose of this trial?

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Research Team

MJ

Mark Jones, MD

Principal Investigator

Incyte Corporation

Eligibility Criteria

This trial is for adults with recurrent or metastatic head and neck squamous cell carcinoma who have measurable disease, are in good physical condition (ECOG 0-1), have proper organ function, and can provide a tumor specimen. It's not for those with recent other cancers, active autoimmune diseases treated within the last 2 years, HIV or hepatitis B/C infections, CNS metastases, or certain types of head and neck cancer.

Inclusion Criteria

My organs are functioning well according to the test results.
Measurable disease based on RECIST v1.1
My oropharyngeal cancer has been tested for HPV.
See 2 more

Exclusion Criteria

I have been treated for an autoimmune disease in the last 2 years.
Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority
My cancer originates from the nasopharynx, salivary gland, or is of an unknown primary origin.
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive pembrolizumab plus epacadostat, pembrolizumab monotherapy, or the EXTREME regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma

Minimum 9 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 14 months

Treatment Details

Interventions

  • 5-Fluorouracil
  • Carboplatin
  • Cetuximab
  • Cisplatin
  • Epacadostat
  • Pembrolizumab
Trial Overview The study compares three treatments: pembrolizumab plus epacadostat; pembrolizumab alone; and the EXTREME regimen (cetuximab with cisplatin/carboplatin plus 5-fluorouracil). The goal is to see which treatment works best as a first-line therapy for this type of cancer.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Pembrolizumab + EpacadostatExperimental Treatment2 Interventions
Group II: PembrolizumabExperimental Treatment1 Intervention
Group III: EXTREMEActive Control4 Interventions
EXTREME regimen includes cetuximab + cisplatin or carboplatin + 5-fluorouracil.

5-Fluorouracil is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as 5-FU for:
  • Colorectal cancer
  • Breast cancer
  • Stomach cancer
  • Pancreatic cancer
  • Ovarian cancer
🇺🇸
Approved in United States as 5-FU for:
  • Colorectal cancer
  • Breast cancer
  • Stomach cancer
  • Pancreatic cancer
🇨🇦
Approved in Canada as 5-FU for:
  • Colorectal cancer
  • Breast cancer
  • Stomach cancer
🇯🇵
Approved in Japan as 5-FU for:
  • Colorectal cancer
  • Breast cancer
  • Stomach cancer
  • Pancreatic cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Incyte Corporation

Lead Sponsor

Trials
408
Recruited
66,800+
Steven Stein profile image

Steven Stein

Incyte Corporation

Chief Medical Officer since 2015

MD from University of Witwatersrand

Hervé Hoppenot profile image

Hervé Hoppenot

Incyte Corporation

Chief Executive Officer since 2014

MBA from ESSEC Business School

Merck Sharp & Dohme LLC

Industry Sponsor

Trials
4,096
Recruited
5,232,000+
Chirfi Guindo profile image

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis profile image

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Findings from Research

In a study of adult patients with metastatic head and neck squamous cell cancer, substituting 5-fluorouracil (5-FU) with a taxane in a pembrolizumab-based treatment regimen did not increase toxicity or worsen survival outcomes.
Patients receiving the taxane combination experienced significantly lower rates of mucositis and elevated creatinine levels compared to those on the 5-FU regimen, indicating a better safety profile for the taxane approach.
Safety outcomes of pembrolizumab with platinum agent chemotherapy combined with 5-fluorouracil or taxane derivative in head and neck cancer.Lee, B., Chehab, SS., Fan, W., et al.[2023]
The combination of carboplatin, oral tegafur, and cetuximab is a safe and well-tolerated first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), with a high compliance rate among patients.
In a study of 104 patients, the treatment resulted in a median overall survival of 11 months and a progression-free survival of 6 months, with an overall response rate of 35%, indicating its efficacy in managing this type of cancer.
Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study.Buxó, E., Sosa, A., Reig, O., et al.[2019]
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the FDA for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), offering a new option with potentially improved efficacy compared to traditional chemotherapy and EGFR inhibitors.
This review discusses the pharmacology and tolerability of pembrolizumab, emphasizing its mechanism of action by blocking the PD-1 receptor, which may enhance the immune response against HNSCC tumors.
Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.Sheth, S., Weiss, J.[2019]

References

Safety outcomes of pembrolizumab with platinum agent chemotherapy combined with 5-fluorouracil or taxane derivative in head and neck cancer. [2023]
Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study. [2019]
Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer. [2019]
Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.). [2014]
Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. [2017]
Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer. [2023]
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. [2018]
Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker. [2022]
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security